Cytotoxicity of paclitaxel in combination with cisplatin and a new Pt-mercaptopyridine complex

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2783-2788

  Ragazzi, E ^a   D'Ancona, S ^a   Berti, E ^a   Carrara, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

cis platin (cis DDP); Drug combination; Paclitaxel; Pt mercaptopyridine Complex (C 2)

Indexed keywords

CISPLATIN; MERCAPTOPYRIDINE COMPLEX; PACLITAXEL; PLATINUM COMPLEX; THIOL DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOTOXICITY; DNA CONFORMATION; DNA CROSS LINKING; DRUG ANTAGONISM; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PYRIDINES; TUMOR CELLS, CULTURED;

EID: 0036765696     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schroder J and Seeber S: Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A: 92-97, 1995
2. Levasseur LM, Greco WR, Rustum YM and Slocum HK: Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells. Cancer Chemother & Pharmacol 40: 495-505, 1997.
3. Gadducci A, Bruhetti I, Cosio S, Riannessi PG, Genazzani AR and Conte P: Platinum compounds and paclitaxel in advanced epithelial ovarian cancer. Anticancer Res 17: 4703-4708, 1997.
4. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M and Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 1282-1293, 1997.
5. Perego P, Romanelli S, Carenino N, Magnani I, Leone R, Bonetti A, Paolicchi A and Zumino F: Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann Oncol 9: 423-430, 1998.
6. Engblom P, Rantanen V, Kulmala J, Helenius H and Grenman S: Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br J Cancer 79: 286-292, 1999.
7. Judson PL, Watson JM, Gehrig PA, Fowler WC and Haskill JS: Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res 59: 2425-2432, 1999.
8. Pu YS, Chen J, Huang CY, Guan JY, Lu SH and Hour TC: Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells. J Urol 165: 2082-2085, 2001.
9. Royer I, Monsarrat B, Sonnier M, Wright M and Cresteil T: Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 56: 58-65, 1996.
10. Mazzo M, Cherchi V, Nicolini M, Sindellari L, Sintran S, Manchiaro PL, D'Ancona S and Berti T: The effect of cis-DDP and Pt-mercaptopyridine complexes on cell lines in vitro. II Farmaco 48: 1631-1640, 1993.
11. Carrara M, Berti T, D'Ancona S, Cherchi V and Sindellari L: In vitro effect of Pt and Pd mercaptopyridine complexes. Anticancer Res 17: 975-980, 1996.
12. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55, 1983.
13. Tallarida RJ and Murray RB: Manual of Pharmacological Calculation with Computer Program. Springer Verlag, New York-Berlin, p. 153-159, 1987.
14. Webb JL: Enzyme and Metabolic Inhibitors. Academic Press, New York, 1963.
15. Le Blanc GA, Sundseth SS, Weber GF and Waxman DJ: Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 52: 540-547, 1992.
16. Peyrot V, Brand C, Crevat A, Braguer D, Chauvet Monges AM and Sari IC: Action of hydrolized cisplatin and some analogs on microtubule protein polymerization in vitro. Cancer Treat Rep 67: 641-646, 1983.
17. Jekunen AP, Christen R, Shalinsky D and Howell SB: Synergistic interaction between cisplatin and taxol in human ovarian carcinoma in vitro. Brit J Cancer 69: 299-306, 1994.
18. Kano Y, Akutsu M, Tsumoda ST, Mori K, Suzuki K and Adaki KI: In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cancer Chemother Pharmacol 37: 525-530, 1996.
19. Kern DH and Morgan CR: Apparent in vitro antagonism between cisplatin and taxol. Proc Am Ass Cancer Res 34: A1788, 1993.
20. Chu QD, Shrayer DP and Wanebo HJ: Biphasic effect of cisplatin and taxol on B16 F10 melanoma. Proc Am Ass Cancer Res 36: A2218, 1995.
21. Chou TC, Otter GM and Sirotnak FM: Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharm 37: 222-228, 1996.
22. Untch M, Sevin BU, Perras JP, Angioli DR, Untch A, Hightower RD, Koechli O and Averette E: Evaluation of paclitaxel (taxol), cis-platin and the combination paclitaxel-cis-platin in ovarian cancer cells in vitro with ATP cell viability assay. Gynecol Oncol 53: 44-49, 1994.
23. Chou TC, Motzer RJ, Tong Y and Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524, 1994.